Richard B. Tenser, Hershey, PA: In the article by Tan et al., 1 atypical illness and poor outcome of HSV encephalitis in immunocompromised patients was likely due to their immune status, and possibly also to antiviralresistant mutant HSV. Acyclovir and related antivirals are phosphorylated by the HSV-encoded thymidine kinase (TK) to the active antiviral state.
However, during HSV infections, mutants arise that are acyclovir resistant primarily because they lack viral TK activity (TK2) and do not phosphorylate acyclovir. 2 In non-immunosuppressed HSV-infected individuals treated with acyclovir, wild-type TK 1 HSV is inhibited by acyclovir, and the small amounts of TK2 HSV that develop are likely controlled by the immune system. However, in immunocompromised individuals, while wild-type TK 1 HSV is inhibited by acyclovir, TK2 mutants likely multiply.
We used an isotope plaque assay to estimate proportions of TK2 and TK1 HSV in lesion swabs from an immunocompromised patient treated with acyclovir.
3 TK2 HSV does not replicate well in nondividing cells but does in replicating cells. In immunocompromised patients, 1 it is suggested that during the period of acyclovir treatment, TK2 HSV probably replicated, more likely in glial cells than in neurons. Presumptive TK2 HSV may have contributed to the atypical clinical course of these patients.
Author Response: Avindra Nath, Bethesda, MD: I thank Dr. Tenser for his comments and for agreeing that acyclovir-resistant HSV may have played a role in the pathophysiology of encephalitis in these patients.
